Efficacy and Safety of Intravenous Treatment of Tuberculosis
Open-label, Randomized, Multicenter, Controlled, Parallel, Comparative Study of Efficacy and Safety of Treatment of Tuberculosis With Isoniazid, Rifampicin, Ethambutol for Intravenous Infusion in Comparison With Oral Forms While the Intensive Phase of Treatment for Patients With Widespread Destructive Pulmonary Tuberculosis With Bacterial Excretion.
Sponsor: Yuria-Pharm
Terminated
According to Sponsor decision.
Listed as NCT04150367, this observational or N/A phase trial focuses on Tuberculosis, Pulmonary and remains terminated or withdrawn. Sponsored by Yuria-Pharm, it has been updated 5 times since 2017, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
5 versions recorded-
Sep 2025 — Present [monthly]
Terminated
-
Sep 2024 — Sep 2025 [monthly]
Terminated
-
Jul 2024 — Sep 2024 [monthly]
Terminated
-
Jan 2021 — Jul 2024 [monthly]
Terminated
-
Dec 2019 — Jan 2021 [monthly]
Terminated
First recorded
Mar 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Yuria-Pharm
For direct contact, visit the study record on ClinicalTrials.gov .